Literature DB >> 27809749

Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides.

Bert Gevaert, Lieselotte Veryser, Frederick Verbeke, Evelien Wynendaele, Bart De Spiegeleer1.   

Abstract

For the first time introduced on the Japanese market, bioactive fish hydrolysates are now available all over the world as food supplements, functional food ingredients or nutricosmeceuticals. They are generally produced from low value fish waste, an almost inexhaustible source of raw material, and are sold as high value products, making them economically interesting from a manufacturer's view point. Most of these products have health or structure/function claims on their packages with different actions like antihypertensive, blood-glucose lowering, anxiolytic, and skin anti-aging activities. Although the different regional legislations all aim to assure consumer safety and prevent misleading of the consumer, the number of legally approved fish hydrolysate containing products drastically differs among different regions. This is because products that have been positively evaluated based on safety and efficacy in one region were found to have not enough evidence for efficacy in another region. These findings call for further international harmonization of the regulation and classification of these products. Moreover, interaction studies of these bioactive products with the normal diet or medicines are generally not performed, keeping the consumer uninformed of the possible risks of combining these products with medicinal products or other food ingredients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27809749     DOI: 10.2174/0929866523666161102122637

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  5 in total

1.  Fish Hydrolysate Supplementation Prevents Stress-Induced Dysregulation of Hippocampal Proteins Relative to Mitochondrial Metabolism and the Neuronal Network in Mice.

Authors:  Julie Le Faouder; Bastien Arnaud; Régis Lavigne; Céline Lucas; Emmanuelle Com; Elodie Bouvret; Anne-Laure Dinel; Charles Pineau
Journal:  Foods       Date:  2022-05-28

2.  Milk‑derived hexapeptide PGPIPN prevents and attenuates acute alcoholic liver injury in mice by reducing endoplasmic reticulum stress.

Authors:  Qia Xu; Hao Xi; Xi Chen; Yin Xu; Peng Wang; Jingwen Li; Wenmei Wei; Fang Gu; Yide Qin
Journal:  Int J Mol Med       Date:  2020-06-16       Impact factor: 4.101

3.  Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress.

Authors:  Nan Qi; Chen Liu; Haoran Yang; Wanrong Shi; Shenyi Wang; Yan Zhou; Cai Wei; Fang Gu; Yide Qin
Journal:  Oncotarget       Date:  2017-09-30

4.  High Throughput Identification of Antihypertensive Peptides from Fish Proteome Datasets.

Authors:  Yunhai Yi; Yunyun Lv; Lijun Zhang; Jian Yang; Qiong Shi
Journal:  Mar Drugs       Date:  2018-10-02       Impact factor: 5.118

Review 5.  Antihypertensive and Angiotensin-I-Converting Enzyme (ACE)-Inhibitory Peptides from Fish as Potential Cardioprotective Compounds.

Authors:  Soheila Abachi; Laurent Bazinet; Lucie Beaulieu
Journal:  Mar Drugs       Date:  2019-10-29       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.